Grand Rounds
A Focus on Special Populations in Relapsed Multiple Myeloma
Mary Steinbach,(1) DNP, APRN, Kathleen Colson,(2) RN, BSN, BS, and Beth Faiman,(3) PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN
From (1)Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; (2)Dana-Farber Cancer Institute, Boston, Massachusetts; (3)Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195. E-mail: faimanb@ccf.org
J Adv Pract Oncol 2022;13(Suppl 4):23–30 |
https://doi.org/10.6004/jadpro.2022.13.5.12 |
© 2022 Harborside™
ABSTRACT
The overall care of patients with multiple myeloma can present similar challenges. However, disparities in health care require that providers consider each individual’s unique circumstances. Disparities based on ethnic/racial group, religion, socioeconomic status, age, sexual orientation or gender identity, or other characteristics can lead to patients receiving less than optimal care and therefore poorer outcomes. Patients who have received more than two lines of therapy can acquire new genetic changes, accelerated cadence of relapse, and suffer from disease sequelae such as pain from prior or ongoing skeletal fractures, recurrent infections, and progressive decline in organ function. Numerous treatment options remain for patients in their first three relapses. Well-designed clinical trials with newer drugs are preferred. Clinicians should discuss clinical trial options and availability with all patients in spite of disparities that may exist. Patients facing disparities are at risk for suboptimal care and should be closely monitored and provided appropriate resources. Continued attention to disease and organ surveillance are critical throughout the course of the disease.
Multiple Myeloma and Plasma Cell Disorders: Update on Diagnosis, Prognosis, Treatment, and Supportive Care
Introduction
A Focus on Newly Diagnosed Multiple Myeloma
A Focus on Relapsed Multiple Myeloma
A Focus on Special Populations in Relapsed Multiple Myeloma
A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
A Focus on Waldenström Macroglobulinemia and AL Amyloidosis
For access to the full length article, please
sign in.
